Use of leflunomide to prevent or control xenograft rejection
OwnerJames Williamsinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of controlling or reversing chronic rejection of allografts in a transplantation patient by administering leflunomide product alone, or in combination with one or more immunosuppressive agents selected from the group consisting of Cyclosporine A, FK506, rapamycin and corticosteroids. The invention also relates to methods of preventing or controlling acute and chronic rejection of xenografts in a transplantation patient by administering leflunomide product alone, or in combination with one or more immunosuppressive agents selected from the group consisting of Cyclosporine A, FK506, rapamycin and corticosteroids.
Claims12
A method of preventing or controlling acute or chronic rejection in a xenograft transplantation patient comprising administering to a patient receiving a xenograft a therapeutically effective amount of leflunomide product.
A method of preventing or controlling acute or chronic rejection in a xenograft transplantation patient comprising administering to a patient receiving a xenograft a therapeutically effective amount of leflunomide product and further comprising administering to the patient a therapeutically effective amount of Cyclosporine A.
Dependencies are inferred from the claim text.